Causes and consequences of microsatellite instability in gastric carcinogenesis

World Journal of Gastroenterology

Volumn 20, Issue 44, 2014, Pages 16433-16442

  Velho, Sérgia ^a   Fernandes, Maria Sofia ^a,b   Leite, Marina ^a   Figueiredo, Ceu ^a,b   Seruca, Raquel ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

Author keywords

Gastric cancer; Helicobacter pylori; Microsatellite instability; Mismatch repair genes; Oncogenes

Indexed keywords

ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; GENE MUTATION; GENE TARGETING; HELICOBACTER INFECTION; HUMAN; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PHENOTYPE; STOMACH CANCER; ANIMAL; CELL TRANSFORMATION; GENETIC PREDISPOSITION; GENETICS; HELICOBACTER PYLORI; MICROBIOLOGY; MUTATION; PATHOGENICITY; PATHOLOGY; PROGNOSIS; RISK FACTOR; STOMACH NEOPLASMS;

TUMOR MARKER;

ANIMALS; BIOMARKERS, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA MISMATCH REPAIR; GENETIC PREDISPOSITION TO DISEASE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICROSATELLITE INSTABILITY; MUTATION; PHENOTYPE; PROGNOSIS; RISK FACTORS; STOMACH NEOPLASMS;

EID: 84918813931     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i44.16433     Document Type: Article

References (118)

1. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993; 363: 558-561 [PMID: 8505985 DOI: 10.1038/363558a0]
2. Jiricny J. The multifaceted mismatch-repair system. Nat Rev Mol Cell Biol 2006; 7: 335-346 [PMID: 16612326 DOI: 10.1038/ nrm1907]
3. Rustgi AK. The genetics of hereditary colon cancer. Genes Dev 2007; 21: 2525-2538 [PMID: 17938238 DOI: 10.1101/ gad.1593107]
4. Peltomäki P. Deficient DNA mismatch repair: a common etiologic factor for colon cancer. Hum Mol Genet 2001; 10: 735-740 [PMID: 11257106]
5. Cannavo E, Marra G, Sabates-Bellver J, Menigatti M, Lipkin SM, Fischer F, Cejka P, Jiricny J. Expression of the MutL homologue hMLH3 in human cells and its role in DNA mismatch repair. Cancer Res 2005; 65: 10759-10766 [PMID: 16322221 DOI: 10.1158/0008-5472.CAN-05-2528]
6. Jeong C, Cho WK, Song KM, Cook C, Yoon TY, Ban C, Fishel R, Lee JB. MutS switches between two fundamentally distinct clamps during mismatch repair. Nat Struct Mol Biol 2011; 18: 379-385 [PMID: 21278758 DOI: 10.1038/nsmb.2009]
7. Plys AJ, Rogacheva MV, Greene EC, Alani E. The unstructured linker arms of Mlh1-Pms1 are important for interactions with DNA during mismatch repair. J Mol Biol 2012; 422: 192-203 [PMID: 22659005 DOI: 10.1016/j.jmb.2012.05.030]
8. Srivatsan A, Bowen N, Kolodner RD. Mispair-specific recruitment of the Mlh1-Pms1 complex identifies repair substrates of the Saccharomyces cerevisiae Msh2-Msh3 complex. J Biol Chem 2014; 289: 9352-9364 [PMID: 24550389 DOI: 10.1074/jbc.M114.552190]
9. Prolla TA, Baker SM, Harris AC, Tsao JL, Yao X, Bronner CE, Zheng B, Gordon M, Reneker J, Arnheim N, Shibata D, Bradley A, Liskay RM. Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair. Nat Genet 1998; 18: 276-279 [PMID: 9500552 DOI: 10.1038/ng0398-276]
10. Räschle M, Marra G, Nyström-Lahti M, Schär P, Jiricny J. Identification of hMutLbeta, a heterodimer of hMLH1 and hPMS1. J Biol Chem 1999; 274: 32368-32375 [PMID: 10542278]
11. Pedrazzani C, Corso G, Velho S, Leite M, Pascale V, Bettarini F, Marrelli D, Seruca R, Roviello F. Evidence of tumor microsatellite instability in gastric cancer with familial aggregation. Fam Cancer 2009; 8: 215-220 [PMID: 19152022 DOI: 10.1007/s10689-008-9231-7]
12. Castells A, Castellvi-Bel S, Balaguer F. Concepts in familial colorectal cancer: where do we stand and what is the future? Gastroenterology 2009; 137: 404-409 [PMID: 19540838 DOI: 10.1053/j.gastro.2009.06.015]
13. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348: 919-932 [PMID: 12621137 DOI: 10.1056/ NEJMra012242]
14. Phelan CM, Iqbal J, Lynch HT, Lubinski J, Gronwald J, Moller P, Ghadirian P, Foulkes WD, Armel S, Eisen A, Neuhausen SL, Senter L, Singer CF, Ainsworth P, Kim-Sing C, Tung N, Llacuachaqui M, Chornokur G, Ping S, Narod SA. Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. Br J Cancer 2014; 110: 530-534 [PMID: 24292448 DOI: 10.1038/bjc.2013.741]
15. Peltomäki P, Vasen H. Mutations associated with HNPCC predisposition - Update of ICG-HNPCC/ INSiGHT mutation database. Dis Markers 2004; 20: 269-276 [PMID: 15528792 DOI: 10.1155/2004/305058]
16. Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, Lee TY, Bodmer D, Hoenselaar E, Hendriks-Cornelissen SJ, Tsui WY, Kong CK, Brunner HG, van Kessel AG, Yuen ST, van Krieken JH, Leung SY, Hoogerbrugge N. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet 2009; 41:112-117 [PMID: 19098912 DOI: 10.1038/ng.283]
17. Gazzoli I, Loda M, Garber J, Syngal S, Kolodner RD. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res 2002; 62: 3925-3928 [PMID: 12124320]
18. Goel A, Nguyen TP, Leung HG, Nagasaka T, Rhees J, Hotchkiss E, Arnold M, Banerji P, Koi M, Kwok CT, Packham D, Lipton L, Boland CR, Ward RL, Hitchins MP. De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one. Int J Cancer 2011; 128: 869-878 [PMID: 20473912 DOI: 10.1002/ijc.25422]
19. Hitchins M, Williams R, Cheong K, Halani N, Lin VA, Packham D, Ku S, Buckle A, Hawkins N, Burn J, Gallinger S, Goldblatt J, Kirk J, Tomlinson I, Scott R, Spigelman A, Suter C, Martin D, Suthers G, Ward R. MLH1 germline epimutations as a factor in hereditary nonpolyposis colorectal cancer. Gastroenterology 2005; 129: 1392-1399 [PMID: 16285940 DOI: 10.1053/j.gastro.2005.09.003]
20. Miyakura Y, Sugano K, Akasu T, Yoshida T, Maekawa M, Saitoh S, Sasaki H, Nomizu T, Konishi F, Fujita S, Moriya Y, Nagai H. Extensive but hemiallelic methylation of the hMLH1 promoter region in early-onset sporadic colon cancers with microsatellite instability. Clin Gastroenterol Hepatol 2004; 2: 147-156 [PMID: 15017620 DOI: 10.1016/ 51542-3565(03)00314-8]
21. Niessen RC, Hofstra RM, Westers H, Ligtenberg MJ, Kooi K, Jager PO, de Groote ML, Dijkhuizen T, Olderode-Berends MJ, Hollema H, Kleibeuker JH, Sijmons RH. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. Genes Chromosomes Cancer 2009; 48: 737-744 [PMID: 19455606 DOI: 10.1002/gcc.20678]
22. Suter CM, Martin DI, Ward RL. Germline epimutation of MLH1 in individuals with multiple cancers. Nat Genet 2004; 36: 497-501 [PMID: 15064764 DOI: 10.1038/ng1342]
23. Lu SL, Kawabata M, Imamura T, Akiyama Y, Nomizu T, Miyazono K, Yuasa Y. HNPCC associated with germline mutation in the TGF-beta type II receptor gene. Nat Genet 1998; 19: 17-18 [PMID: 9590282 DOI: 10.1038/ng0598-17]
24. Pinto M, Wu Y, Mensink RG, Cirnes L, Seruca R, Hofstra RM. Somatic mutations in mismatch repair genes in sporadic gastric carcinomas are not a cause but a consequence of the mutator phenotype. Cancer Genet Cytogenet 2008; 180: 110-114 [PMID: 18206535 DOI: 10.1016/j.cancergencyto.2007 .09.022]
25. Gu M, Kim D, Bae Y, Choi J, Kim S, Song S. Analysis of microsatellite instability, protein expression and methylation status of hMLH1 and hMSH2 genes in gastric carcinomas. Hepatogastroenterology 2009; 56: 899-904 [PMID: 19621725]
26. Leite M, Corso G, Sousa S, Milanezi F, Afonso LP, Henrique R, Soares JM, Castedo S, Carneiro F, Roviello F, Oliveira C, Seruca R. MSI phenotype and MMR alterations in familial and sporadic gastric cancer. Int J Cancer 2011; 128: 1606-1613 [PMID: 20533283 DOI: 10.1002/ijc.25495]
27. Pinto M, Oliveira C, Machado JC, Cirnes L, Tavares J, Carneiro F, Hamelin R, Hofstra R, Seruca R, Sobrinho-Simöes M. MSI-L gastric carcinomas share the hMLH1 methylation status of MSI-H carcinomas but not their clinicopathological profile. Lab Invest 2000; 80: 1915-1923 [PMID: 11140703 DOI: 10.1038/labinvest.3780201]
28. Bevilacqua RA, Simpson AJ. Methylation of the hMLH1 promoter but no hMLH1 mutations in sporadic gastric carcinomas with high-level microsatellite instability. Int J Cancer 2000; 87: 200-203 [PMID: 10861474 DOI: 10.1002/1097-0215(2 0000715)87]
29. Machado AM, Figueiredo C, Seruca R, Rasmussen LJ. Helicobacter pylori infection generates genetic instability in gastric cells. Biochim Biophys Acta 2010; 1806: 58-65 [PMID: 20122996 DOI: 10.1016/j.bbcan.2010.01.007]
30. Machado AM, Figueiredo C, Touati E, Máximo V, Sousa S, Michel V, Carneiro F, Nielsen FC, Seruca R, Rasmussen LJ. Helicobacter pylori infection induces genetic instability of nuclear and mitochondrial DNA in gastric cells. Clin Cancer Res 2009; 15: 2995-3002 [PMID: 19383819 DOI: 10.1158/1078-0432. CCR-08-2686]
31. Covacci A, Telford JL, Del Giudice G, Parsonnet J, Rappuoli R. Helicobacter pylori virulence and genetic geography. Science 1999; 284: 1328-1333 [PMID: 10334982 DOI: 10.1126/science.284.5418.1328]
32. Peek RM, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002; 2: 28-37 [PMID: 11902583 DOI: 10.1038/nrc703]
33. Machado JC, Pharoah P, Sousa S, Carvalho R, Oliveira C, Figueiredo C, Amorim A, Seruca R, Caldas C, Carneiro F, Sobrinho-Simöes M. Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology 2001; 121: 823-829 [PMID: 11606496 DOI: 10.1053/gast.2001.28000]
34. Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology 2007; 133: 659-672 [PMID: 17681184 DOI: 10.1053/j.gastro.2007.06.026]
35. Figueiredo C, Machado JC, Pharoah P, Seruca R, Sousa S, Carvalho R, Capelinha AF, Quint W, Caldas C, van Doom LJ, Carneiro F, Sobrinho-Simöes M. Helicobacter pylori and interleukin 1 genotyping: an opportunity to identify high-risk individuals for gastric carcinoma. J Natl Cancer Inst 2002; 94:1680-1687 [PMID: 12441323 DOI: 10.1093/jnci/94.22.1680]
36. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009; 30: 1073-1081 [PMID: 19468060 DOI: 10.1093/carcin/bgp127bgp127]
37. Chiba T, Marusawa H, Ushijima T. Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation. Gastroenterology 2012; 143: 550-563 [PMID: 22796521 DOI: 10.1053/ j.gastro.2012.07.009]
38. Sepulveda AR. Helicobacter, Inflammation, and Gastric Cancer. Curr Pathobiol Rep 2013; 1: 9-18 [PMID: 23687623 DOI: 10.1007/s40139-013-0009-8]
39. Davies GR, Simmonds NJ, Stevens TR, Sheaff MT, Banatvala N, Laurenson IF, Blake DR, Rampton DS. Helicobacter pylori stimulates antral mucosal reactive oxygen metabolite production in vivo. Gut 1994; 35: 179-185 [PMID: 8307467 DOI: 10.1136/gut.35.2.179]
40. Smoot DT, Elliott TB, Verspaget HW, Jones D, Allen CR, Vernon KG, Bremner T, Kidd LC, Kim KS, Groupman JD, Ashktorab H. Influence of Helicobacter pylori on reactive oxygen-induced gastric epithelial cell injury. Carcinogenesis 2000; 21: 2091-2095 [PMID: 11062173 DOI: 10.1093/carcin/21.11.2091]
41. Obst B, Wagner S, Sewing KF, Beil W. Helicobacter pylori causes DNA damage in gastric epithelial cells. Carcinogenesis 2000; 21: 1111-1115 [PMID: 10836997 DOI: 10.1093/carcin/21.6.1111]
42. Khanzode SS, Khanzode SD, Dakhale GN. Serum and plasma concentration of oxidant and antioxidants in patients of Helicobacter pylori gastritis and its correlation with gastric cancer. Cancer Lett 2003; 195: 27-31 [PMID: 12767508 DOI: 10.1016/50304-3835(03)00147-2]
43. Touati E, Michel V, Thiberge JM, Wuscher N, Huerre M, Labigne A. Chronic Helicobacter pylori infections induce gastric mutations in mice. Gastroenterology 2003; 124: 1408-1419 [PMID: 12730880 DOI: 10.1016/S0016-5085(03)00266-X]
44. Izzotti A, De Flora S, Cartiglia C, Are BM, Longobardi M, Camoirano A, Mura I, Dore MP, Scanu AM, Rocca PC, Maida A, Piana A. Interplay between Helicobacter pylori and host gene polymorphisms in inducing oxidative DNA damage in the gastric mucosa. Carcinogenesis 2007; 28: 892-898 [PMID: 17127715]
45. Handa O, Naito Y, Yoshikawa T. Redox biology and gastric carcinogenesis: the role of Helicobacter pylori. Redox Rep 2011; 16:1-7 [PMID: 21605492 DOI: 10.1179/174329211X1296 8219310756]
46. Park S, Han SU, Lee KM, Park KH, Cho SW, Hahm KB. 5-LOX inhibitor modulates the inflammatory responses provoked by Helicobacter pylori infection. Helicobacter 2007; 12: 49-58 [PMID: 17241301 DOI: 10.1111/j.1523-5378.2007.00469. x]
47. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006; 72: 1605-1621 [PMID: 16889756 DOI: 10.1016/ j.bcp.2006.06.029]
48. Yao Y, Tao H, Park DI, Sepulveda JL, Sepulveda AR. Demonstration and characterization of mutations induced by Helicobacter pylori organisms in gastric epithelial cells. Helicobacter 2006; 11: 272-286 [PMID: 16882331 DOI: 10.1111/ j,1523-5378.2006.00408.x]
49. Machado AM, Desler C, Boggild S, Strickertsson JA, FriisHansen L, Figueiredo C, Seruca R, Rasmussen LJ. Helicobacter pylori infection affects mitochondrial function and DNA repair, thus, mediating genetic instability in gastric cells. Mech Ageing Dev 2013; 134: 460-466 [PMID: 24012633 DOI: 10.1016/j.mad.2013.08.004]
50. Hiyama T, Tanaka S, Shima H, Kose K, Tuncel H, Ito M, Kitadai Y, Sumii M, Yoshihara M, Shimamoto F, Harama K, Chayama K. Somatic mutation in mitochondrial DNA and nuclear microsatellite instability in gastric cancer. Oncol Rep 2003; 10:1837-1841 [PMID: 14534705]
51. Park DI, Park SH, Kim SH, Kim JW, Cho YK, Kim HJ, Sohn Cl, Jeon WK, Kim BI, Cho EY, Kim EJ, Chae SW, Sohn JH, Sung IK, Sepulveda AR, Kim JJ. Effect of Helicobacter pylori infection on the expression of DNA mismatch repair protein. Helicobacter 2005; 10:179-184 [PMID: 15904475 DOI: 10.1111/ ].1523-5378.2005.00309.x]
52. Kim JJ, Tao H, Carloni E, Leung WK, Graham DY, Sepulveda AR. Helicobacter pylori impairs DNA mismatch repair in gastric epithelial cells. Gastroenterology 2002; 123: 542-553 [PMID: 12145807 DOI: 10.1053/gast.2002.34751]
53. Mirzaee V, Molaei M, Shalmani HM, Zali MR. Helicobacter pylori infection and expression of DNA mismatch repair proteins. World J Gastroenterol 2008; 14: 6717-6721 [PMID: 19034977 DOI: 10.3748/wjg.14.6717]
54. Lee S, Shin MG, Jo WH, Kim MJ, Kim HR, Lee WS, Park DH, Won JH, Shin JH, Suh SP, Ryang DW. Association between Helicobacter pylori-related peptic ulcer tissue and somatic mitochondrial DNA mutations. Clin Chem 2007; 53:1390-1392 [PMID: 17582156 DOI: 10.1373/clinchem.2007.088047]
55. Woerner SM, Benner A, Sutter C, Schiller M, Yuan YP, Keller G, Bork P, Doeberitz Mv, Gebert JF. Pathogenesis of DNA repair-deficient cancers: a statistical meta-analysis of putative Real Common Target genes. Oncogene 2003; 22: 2226-2235 [PMID: 12700659 DOI: 10.1038/sj.onc.12064211206421]
56. Perucho M. Tumors with microsatellite instability: many mutations, targets and paradoxes. Oncogene 2003; 22: 2223-2225 [PMID: 12700658 DOI: 10.1038/sj.onc.12065801206580]
57. Imai K, Yamamoto H. Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 2008; 29: 673-680 [PMID: 17942460 DOI: 10.1093/carcin/bgm228]
58. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meitzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248-5257 [PMID: 9823339]
59. Duval A, Rolland S, Compoint A, Tubacher E, Iacopetta B, Thomas G, Hamelin R. Evolution of instability at coding and non-coding repeat sequences in human MSI-H colorectal cancers. Hum Mol Genet 2001; 10: 513-518 [PMID: 11181575 DOI: 10.1093/hmg/10.5.513]
60. Woerner SM, Yuan YP, Benner A, Korff S, von Knebel Doeberitz M, Bork P. SelTarbase, a database of human mononucleotide-microsatellite mutations and their potential impact to tumorigenesis and immunology. Nucleic Acids Res 2010; 38: D682-D689 [PMID: 19820113 DOI: 10.1093/nar/gkp839gkp839]
61. Kim MS, Oh JE, Kim YR, Park SW, Kang MR, Kim SS, Ahn CH, Yoo NJ, Lee SH. Somatic mutations and losses of expression of microRNA regulation-related genes AG02 and TNRC6A in gastric and colorectal cancers, J Pathol 2010; 221: 139-146 [PMID: 20198652 DOI: 10.1002/path.2683]
62. Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, Chan TL, Kan Z, Chan AS, Tsui WY, Lee SP, Ho SL, Chan AK, Cheng GH, Roberts PC, Rejto PA, Gibson NW, Pocalyko DJ, Mao M, Xu J, Leung SY. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 2011; 43:1219-1223 [PMID: 22037554 DOI: 10.1038/ ng.982]
63. Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi ST, Siu HC, Deng S, Chu KM, Law S, Chan KH, Chan AS, Tsui WY, Ho SL, Chan AK, Man JL, Foglizzo V, Ng MK, Chan AS, Ching YP, Cheng GH, Xie T, Fernandez J, Li VS, Clevers H, Rejto PA, Mao M, Leung SY. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nat Genet 2014; 46: 573-582 [PMID: 24816253 DOI: 10.1038/ng.2983]
64. Velho S, Corso G, Oliveira C, Seruca R. KRAS signaling pathway alterations in microsatellite unstable gastroin-testinal cancers. Adv Cancer Res 2010; 109: 123-143 [PMID: 21070916 DOI: 10.1016/B978-0-12-380890-5.00004-1]
65. Corso G, Velho S, Paredes J, Pedrazzani C, Martins D, Milanezi F, Pascale V, Vindigni G, Pinheiro H, Leite M, Marrelli D, Sousa S, Carneiro F, Oliveira C, Roviello F, Seruca R. Oncogenic mutations in gastric cancer with microsatellite instability. Eur J Cancer 2011; 47: 443-451 [PMID: 20937558 DOI: 10.1016/ j.ejca.2010.09.008]
66. Liu J, McCleland M, Stawiski EW, Gnad F, Mayba O, Haverty PM, Durinck S, Chen YJ, Klijn G, Jhunjhunwala S, Lawrence M, Liu H, Wan Y, Chopra V, Yaylaoglu MB, Yuan W, Ha C, Gilbert HN, Reeder J, Pau G, Stinson J, Stern HM, Manning G, Wu TD, Neve RM, de Sauvage FJ, Modrusan Z, Seshagiri S, Firestein R, Zhang Z. Integrated exorne and transcriptome sequencing reveals ZAK isoform usage in gastric cancer. Nat Commun 2014; 5: 3830 [PMID: 24807215 DOI: 10.1038/ncomms4830]
67. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-1174 [PMID: 18337605 DOI: 10.1056/NEJMra0707704]
68. Becker JC, Müller-Tidow G, Stolte M, Fujimori T, Tidow N, Ilea AM, Brandts C, Tickenbrock L, Serve H, Berdel WE, Domschke W, Pohle T. Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer. Int J Oncol 2006; 29: 615-623 [PMID: 16865277]
69. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB, Zhang S, Lee M, Wu J, Lim KH, Lei Z, Goh G, Lim QY, Tan AL, Sin Poh DY, Riahi S, Bell S, Shi MM, Linnartz R, Zhu F, Yeoh KG, Toh HC, Yong WP, Cheong HC, Rha SY, Boussioutas A, Grabsch H, Rozen S, Tan P. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012; 61: 673-684 [PMID: 22315472 DOI: 10.1136/gutjnl-2011-301839]
70. Moutinho C, Mateus AR, Milanezi F, Carneiro F, Seruca R, Suriano G. Epidermal growth factor receptor structural alterations in gastric cancer. BMC Cancer 2008; 8: 10 [PMID: 18199332 DOI: 10.1186/1471-2407-8-10]
71. Liu Z, Liu L, Li M, Wang Z, Feng L, Zhang Q, Cheng S, Lu S. Epidermal growth factor receptor mutation in gastric cancer. Pathology 2011; 43: 234-238 [PMID: 21436633 DOI: 10.1097/ PAT. 0b013e328344e61b]
72. Mammano E, Belluco C, Sciro M, Mencarelli R, Agostini M, Michelotto M, Marchet A, Nitti D. Epidermal growth factor receptor (EGFR): mutational and protein expression analysis in gastric cancer. Anticancer Res 2006; 26: 3547-3550 [PMID: 17094480]
73. Yuan Z, Shin J, Wilson A, Goel S, Ling YH, Ahmed N, Dopeso H, Jhawer M, Nasser S, Montagna C, Fordyce K, Augenlicht LH, Aaltonen LA, Arango D, Weber TK, Mariadason JM. An A13 repeat within the 3'-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression. Cancer Res 2009; 69: 7811-7818 [PMID: 19789347 DOI: 10.1158/0008-5472.CAN-09-0986]
74. Oliveira C, Pinto M, Duval A, Brennetot C, Domingo E, Espin E, Armengol M, Yamamoto H, Hamelin R, Seruca R, Schwartz S. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 2003; 22: 9192-9196 [PMID: 14668801 DOI: 10.1038/sj.onc.1207061]
75. van Grieken NC, Aoyama T, Chambers PA, Bottomley D, Ward LG, Inam I, Buffart TE, Das K, Lim T, Pang B, Zhang SL, Tan IB, Carvalho B, Heideman DA, Miyagi Y, Kameda Y, Arai T, Meijer GA, Tsuburaya A, Tan P, Yoshikawa T, Grabsch HI. KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: results from a large international multicentre study. Br J Cancer 2013; 108: 1495-1501 [PMID: 23511561 DOI: 10.1038/bjc.2013.109]
76. Brennetot C, Duval A, Hamelin R, Pinto M, Oliveira C, Seruca R, Schwartz S. Frequent Ki-ras mutations in gastric tumors of the MSI phenotype. Gastroenterology 2003; 125: 1282 [PMID: 14552318]
77. Gylling A, Abdel-Rahman WM, Juhola M, Nuorva K, Hautala E, Järvinen HJ, Mecklin JP, Aarnio M, Peltomäki P. Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study. Gut 2007; 56: 926-933 [PMID: 17267619 DOI: 10.1136/ gut.2006.114876]
78. Lee SH, Lee JW, Soung YH, Kim HS, Park WS, Kim SY, Lee JH, Park JY, Cho YG, Kim CJ, Nam SW, Kim SH, Lee JY, Yoo NJ. BRAF and KRAS mutations in stomach cancer. Oncogene 2003; 22: 6942-6945 [PMID: 14534542 DOI: 10.1038/ sj.onc.1206749]
79. Wu M, Semba S, Oue N, Ikehara N, Yasui W, Yokozaki H. BRAF/K-ras mutation, microsatellite instability, and promoter hypermethylation of hMLH1/MGMT in human gastric carcinomas. Gastric Cancer 2004; 7: 246-253 [PMID: 15616773 DOI: 10.1007/s10120-004-0300-9]
80. Zhao W, Chan TL, Chu KM, Chan AS, Stratton MR, Yuen ST, Leung SY. Mutations of BRAF and KRAS in gastric cancer and their association with microsatellite instability. Int J Cancer 2004; 108: 167-169 [PMID: 14618633 DOI: 10.1002/ ijc.11553]
81. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554 [PMID: 15016963 DOI: 10.1126/ science.1096502]
82. Li VS, Wong GW, Chan TL, Chan AS, Zhao W, Chu KM, So S, Chen X, Yuen ST, Leung SY. Mutations of PIK3CA in gastric adenocarcinoma. BMC Cancer 2005; 5: 29 [PMID: 15784156 DOI: 10.1186/1471-2407-5-29]
83. Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G, Schwartz S, Duval A, Carneiro F, Machado JC, Hamelin R, Seruca R. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005; 41: 1649-1654 [PMID: 15994075 DOI: 10.1016/j.ejca.2005.04.022]
84. Sukawa Y, Yamamoto H, Nosho K, Kunimoto H, Suzuki H, Adachi Y, Nakazawa M, Nobuoka T, Kawayama M, Mikami M, Matsuno T, Hasegawa T, Hirata K, Imai K, Shinomura Y. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer. World J Gastroenterol 2012; 18: 6577-6586 [PMID: 23236232 DOI: 10.3748/wjg.v18.i45.6577]
85. Lee J, van Hummelen P, Go C, Palescandolo E, Jang J, Park HY, Kang SY, Park JO, Kang WK, MacConaill L, Kim KM. High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS One 2012; 7: e38892 [PMID: 22723903 DOI: 10.1371/journal, pone.0038892]
86. Shi J, Yao D, Liu W, Wang N, Lv H, Zhang G, Ji M, Xu L, He N, Shi B, Hou P. Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer 2012; 12: 50 [PMID: 22292935 DOI: 10.1186/1471-2407-12-50]
87. Barbi S, Cataldo I, De Manzoni G, Bersani S, Lamba S, Mattuzzi S, Bardelli A, Scarpa A. The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Cancer Res 2010; 29: 32 [PMID: 20398348 DOI: 10.1186/1756-9966-29-32]
88. Chong ML, Loh M, Thakkar B, Pang B, Iacopetta B, Soong R. Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: meta-analysis, co-occurrence and ethnic variation. Int J Cancer 2014; 134: 1232-1238 [PMID: 23960014 DOI: 10.1002/ijc.28444]
89. Chadee DN, Kyriakis JM. A novel role for mixed lineage kinase 3 (MLK3) in B-Raf activation and cell proliferation. Cell Cycle 2004; 3: 1227-1229 [PMID: 15467451]
90. Velho S, Oliveira C, Paredes J, Sousa S, Leite M, Matos P, Milanezi F, Ribeiro AS, Mendes N, Licastro D, Karhu A, Oliveira MJ, Ligtenberg M, Hamelin R, Carneiro F, Lindblom A, Peltomaki P, Castedo S, Schwartz S, Jordan P, Aaltonen LA, Hofstra RM, Suriano G, Stupka E, Fialho AM, Seruca R. Mixed lineage kinase 3 gene mutations in mismatch repair deficient gastrointestinal tumours. Hum Mol Genet 2010; 19: 697-706 [PMID: 19955118 DOI: 10.1093/hmg/ddp536]
91. Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol 2013; 10: 643-655 [PMID: 24061039 DOI: 10.1038/nrclinonc.2013.170]
92. Ottini L, Falchetti M, Lupi R, Rizzolo P, Agnese V, Colucci G, Bazan V, Russo A. Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol 2006; 17 Suppl 7: vn97-vi102 [PMID: 16760303 DOI: 10.1093/ annonc/mdl960]
93. Kim H, An JY, Noh SH, Shin SK, Lee YC, Kim H. High microsatellite instability predicts good prognosis in intestinaltype gastric cancers. J Gastroenterol Hepatol 2011; 26: 585-592 [PMID: 21332554 DOI: 10.1111/j.1440-1746.2010.06487.x]
94. dos Santos NR, Seruca R, Constancia M, Seixas M, SobrinhoSimões M. Microsatellite instability at multiple loci in gastric carcinoma: clinicopathologic implications and prognosis. Gastroenterology 1996; 110: 38-44 [PMID: 8536886]
95. Oliveira C, Seruca R, Seixas M, Sobrinho-Simões M. The clinicopathological features of gastric carcinomas with microsatellite instability may be mediated by mutations of different "target genesquot;: a study of the TGFbeta RII, IGFII R, and BAX genes. Am J Pathol 1998; 153: 1211-1219 [PMID: 9777952]
96. Seruca R, Santos NR, David L, Constância M, Barroca H, Carneiro F, Seixas M, Peltomaki P, Lothe R, Sobrinho-Simöes M. Sporadic gastric carcinomas with microsatellite instability display a particular clinicopathologic profile. Int J Cancer 1995; 64: 32-36 [PMID: 7665246]
97. Beghelli S, de Manzoni G, Barbi S, Tomezzoli A, Roviello F, Di Gregorio C, Vindigni C, Bortesi L, Parisi A, Saragoni L, Scarpa A, Moore PS. Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. Surgery 2006; 139: 347-356 [PMID: 16546499 DOI: 10.1016/j.surg.2005.08.021]
98. Durães C, Almeida GM, Seruca R, Oliveira C, Carneiro F. Biomarkers for gastric cancer: prognostic, predictive or targets of therapy? Virchows Arch 2014; 464: 367-378 [PMID: 24487788 DOI: 10.1007/s00428-013-1533-y]
99. Inokuchi Ml, Murayama T, Hayashi M, Takagi Y, Kato K, Enjoji M, Kojima K, Kumagai J, Sugihara K. Prognostic value of co-expression of STAT3, mTOR and EGFR in gastric cancer. Exp Ther Med 2011; 2: 251-256 [PMID: 22977493 DOI: 10.3892/ etm.2011.187]
100. Matsubara J, Yamada Y, Nakajima TE, Kato K, Hamaguchi T, Shirao K, Shimada Y, Shimoda T. Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology 2008; 74: 76-83 [PMID: 18544998 DOI: 10.1159/000139127]
101. Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H, Sasako M. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 2012; 18: 5992-6000 [PMID: 22977193 DOI: 10.1158/ 1078-0432.CCR-12-1318]
102. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F, Galizia G. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 2008; 15: 69-79 [PMID: 17896140 DOI: 10.1245/ s10434-007-9596-0]
103. Atmaca A, Werner D, Pauligk C, Steinmetz K, Wirtz R, Altmannsberger HM, Jäger E, Al-Batran SE. The prognostic impact of epidermal growth factor receptor in patients with metastatic gastric cancer. BMC Cancer 2012; 12: 524 [PMID: 23153332 DOI: 10.1186/1471-2407-12-524]
104. Jácome AA, Wohnrath DR, Scapulatempo Neto C, Carneseca EC, Serrano SV, Viana LS, Nunes JS, Martinez EZ, Santos JS. Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors. Gastric Cancer 2014; 17: 76-86 [PMID: 23455716 DOI: 10.1007/s10120-013-0236-z]
105. Hong L, Han Y, Yang J, Zhang H, Jin Y, Brain L, Li M, Zhao Q. Prognostic value of epidermal growth factor receptor in patients with gastric cancer: a meta-analysis. Gene 2013; 529: 69-72 [PMID: 23954221 DOI: 10.1016/j.gene.2013.07.106]
106. Barros-Silva JD, Leitão D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, Bento MJ, Santos L, Ferreira P, Rêgo S, Brandão C, Carneiro F, Lopes C, Schmitt F, Teixeira MR. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009; 100: 487-493 [PMID: 19156142 DOI: 10.1038/sj.bjc.6604885]
107. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Müller W. HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. Cell Oncol 2010; 32: 57-65 [PMID: 20208134 DOI: 10.3233/CLO-2009-0497]
108. Ji YN, Wang Q, Li Y, Wang Z. Prognostic value of vascular endothelial growth factor A expression in gastric cancer: a meta-analysis. Tumour Biol 2014; 35: 2787-2793 [PMID: 24234334 DOI: 10.1007/s13277-013-1371-1]
109. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996; 77: 858-863 [PMID: 8608475]
110. Chang WJ, Du Y, Zhao X, Ma LY, Cao GW. Inflammationrelated factors predicting prognosis of gastric cancer. World J Gastroenterol 2014; 20: 4586-4596 [PMID: 24782611 DOI: 10.3748/wjg.v20.il6.4586]
111. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010; (3): CD004064 [PMID: 20238327 DOI: 10.1002/14651858.CD004064.pub3]
112. Carethers JM, Chauhan DP, Fink D, Nebel S, Bresalier RS, Howell SB, Boland CR. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 1999; 117: 123-131 [PMID: 10381918]
113. An JY, Kim H, Cheong JH, Hyung WJ, Kim H, Noh SH. Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. Int J Cancer 2012; 131: 505-511 [PMID: 21898388 DOI: 10.1002/ijc.26399]
114. Oki E, Kakeji Y, Zhao Y, Yoshida R, Ando K, Masuda T, Ohgaki K, Morita M, Maehara Y. Chemosensitivity and survival in gastric cancer patients with microsatellite instability. Ann Surg Oncol 2009; 16: 2510-2515 [PMID: 19565284 DOI: 10.1245/ S10434-009-0580-8]
115. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or g astro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]
116. Liu L, Wu N, Li J. Novel targeted agents for gastric cancer. J Hematol Oncol 2012; 5: 31 [PMID: 22709792 DOI: 10.1186/1756-8722-5-31]
117. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Gelik I, Götte H, Melezínková H, Moehler M. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14: 490-499 [PMID: 23594786 DOI: 10.1016/ 51470-2045(13)70102-5]
118. Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt G, Barbachano Y. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 2013; 14: 481-489 [PMID: 23594787 DOI: 10.1016/51470-2045(13)70096-2]